Mazda just unveiled its 2018 Mazda6 at the Los Angeles Auto Show and Masahiro Moro, President and CEO of the company’s North American Operations, told us everything about the new car and the automaker’s ambitions. While many in the industry are rushing into self-driving vehicles, currently Mazda is not moving into that direction yet. "I think autonomous driving in future technology is underway,” he said. But he points out the new Mazda6 will have other “fantastic” premium features, a theme that will elevate the company into a higher-end market. The model introduces the 2.5-liter turbocharged gasoline engine, which offers better fuel efficiency. Its engineering will provide more power and sensation for the driving experience, says Moro. He added that this mid-size sedan is ideal for a family or anyone who enjoys the pleasure of driving.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More